Quick Summary — ALT scores higher on quality with 4.7/10 vs ANNX's 4.2/10. ALT trades at $2.90 while ANNX trades at $5.26. Both analyzed daily using SEC EDGAR data across 13 institutional models.
ALT scores higher with a 4.7/10 quality rating vs ANNX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $2.90, ALT trades +67.2% above its Bayesian DCF fair value of $0.95, while ANNX at $5.26 trades +63.7% above its estimate of $1.91. ALT shows a wider gap between price and intrinsic value.
ALT earns a Quality of Company score of 4.7/10 compared to ANNX's 4.2/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
ALT carries a WARN value trap risk (47/100) while ANNX shows LOW risk (36/100). Stocks with value trap scores above 40 may appear undervalued but face deteriorating fundamentals — declining margins, rising debt, or shrinking revenue can make the apparent discount a trap.
Both ALT and ANNX operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare ALT vs ANNX differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.